Marketed package NDCs are listings for this exact FDA generic-name string (and dosage form, when one is selected) that are in the current directory file and are finished products — bulk ingredients, export-only and further-processing listings are excluded and counted separately. Makers are distinct labeler names seen in the last 30 days minus classified repackagers/relabelers; a listing is not proof of shipping volume. To check: search the generic name in FDA's NDC Directory and count labelers.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
55 companies list this market (plus 2 repackagers, which add no supply) — deep enough that no single failure threatens the supply.The price has fallen 31% in a year, to $0.1009 per unit.
ⓘ How this was built
Data sources
FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
CMS NADAC — latest price vs the price in effect ~12 months earlier
FDA drug shortages and enforcement reports (openFDA)
FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Method
Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Each package (NDC) of this drug has its own NADAC — CMS’s survey of what retail pharmacies paid on invoices. The line follows the median NDC; the shaded band holds the middle half of NDC prices — the wider it is, the more they disagree.
Latest published · Aug 2026 — typical price $0.1009 · middle half $0.1009–$0.1029 · full range $0.0678–$0.1029 · 11 NDCs · 57 labelers
middle half of NDC pricestypical (median) pricelabelers with an open FDA marketing window, repackagers excluded — products still listed today only, so past exits are invisible (bottom lane)Priced per unitⓘPrices are for one unit — a single tablet, capsule, vial, or device (NADAC calls this “each”).· not shown: 2 NDCs priced per mL (pick a dosage form above to see them)Source: CMS NADAC — monthly means to Nov 2024, weekly file after; each NDC’s last price carried up to 6 months
ⓘ How this was built
Data sources
CMS NADAC weekly files (data.medicaid.gov), December 2024 onward — one row per NDC when its price changes
CMS NADAC per-year archive files, 2013 – November 2024, averaged per NDC per month
CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the multiple-source group
FDA NDC Directory marketing start/end dates + derived.labeler_kinds (bottom lane)
Method
Each month, every NDC of this drug priced in the band's unit (EA) contributes its NADAC in effect that month — the price published that month, or its last published price carried forward for up to 6 months (the readout says how many were carried). The band is the minimum, quartiles, median and maximum across those NDCs, so repackagers' relistings count as separate NDCs; brand and generic are split by FDA marketing category, with an NDA/BLA product counted as brand only when sold under a name other than the generic name. The series ends at the newest month with a published row. Before December 2024 each point is the mean of that NDC's archived weekly rows for the month; from December 2024 CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market (dashed marker). NDCs whose archive rows predate the weekly file borrow the market's dominant unit, which can misplace a liquid among tablets in mixed-unit markets. The bottom lane counts labelers with an open FDA marketing window that month, repackagers excluded, among products still in today's directory — earlier exits are invisible, so the lane rises over time by construction. To check a month: download that month's NADAC file and filter to this drug's NDCs.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
The latest 40 of 63 detected changes for glycerin, newest first — price moves, shortages, recalls, and labelers entering or leaving. Detected by comparing each day’s federal data against what we already held.
ⓘ How this was built
Data sources
DrugDashboards change feed — daily diffs of the NDC Directory, NADAC, FDA shortages and enforcement reports, Part D formularies
Method
Events whose NDC belongs to a product with this generic-name string, dated by the day the change was detected (the file's own effective date is shown on price rows). Generic NADAC is a 3-month moving average since December 2024, so most price moves here are small and lag the market.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
NADAC $0.0975 → $0.1009 per EA (+3.54%) · effective Aug 19, 2026
Aug 19, 2026
Same drug class
Other molecules FDA puts in Non-Standardized Chemical Allergen, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
ⓘ How this was built
Data sources
FDA NDC Directory pharmacologic class (EPC) per product
FDA drug shortages (openFDA)
FDA NDC Directory labelers + derived.labeler_kinds
Method
Peers share this drug's most common Established Pharmacologic Class. 'In shortage' means an FDA Current row whose NDC belongs to that molecule or whose listing name normalizes to it (any presentation). Maker counts are labelers active in the last 30 days minus repackagers, across all forms.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No. FDA's shortage list has no current entry for Glycerin under this name or its presentations. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Glycerin?
55 companies have listed Glycerin in the FDA NDC Directory in the last 30 days, not counting 2 repackagers that relist other makers' products. A listing is not proof of volume; the products below show every listed package.
What does Glycerin cost?
The typical pharmacy pays about $0.1009 per unit for Glycerin — the median of 11 package NDCs' latest CMS NADAC prices (last 6 months, unit-priced products only). That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
ⓘ How this was built
Data sources
FDA drug shortages (openFDA)
FDA NDC Directory + derived.labeler_kinds
CMS NADAC weekly file
Method
Shortage: any Current FDA row whose package NDC belongs to this generic-name string or whose listing name normalizes to the same molecule; the presentations named are those rows. Makers: distinct labelers listing this string in the last 30 days, repackagers excluded. Cost: the median of each NDC's most recent NADAC within 6 months, restricted to the market's most common billing unit and to the generic cohort when one exists.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
All marketed products
204 marketed NDCs, every one listed. NADAC prices show the file date; prices older than 6 months are greyed.
ⓘ How this was built
Data sources
FDA NDC Directory (openFDA) — products, packages, labelers, marketing category, TE code (application-level)
CMS NADAC — each NDC's latest price
DrugDashboards fragility v1 score
Method
Finished products currently in the NDC Directory under this generic-name string (bulk, export-only and further-processing listings excluded). 'Widely marketed' marks the four form/strength/package combinations with the most NADAC-priced NDCs — a proxy for retail availability, not dispensing volume. Labeler counts in the tree include repackagers, marked in the roster on each drug page.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Expand a strength to see its dosage forms, then package sizes, then each labeler and NDC (labelers include repackagers). Click an NDC for its full detail page.